A meta-analysis of 9 clinical trials (593 patients) found psilocybin therapy led to a small but significant reduction in suicidal thoughts compared to control groups (SMD = −0.24). No suicide attempts or deaths were reported across studies. The benefit appeared consistent regardless of diagnosis, though most trials were short-term and excluded people with severe baseline suicidality. These findings suggest psilocybin may offer a valuable new tool for reducing suicide risk in psychiatric populations.